Astrazeneca PLC (AZN) SEC Filings — 2025
44 SEC filings for Astrazeneca PLC (AZN) in 2025.
Filings
- Astrazeneca PLC 6-K Filing — 6-K · Dec 22, 2025
- Astrazeneca PLC 6-K Filing — 6-K · Dec 19, 2025
- Enhertu Gets US Approval for 1st-Line HER2+ Breast Cancer — 6-K · Dec 16, 2025
- AstraZeneca PLC Files 6-K Report — 6-K · Dec 4, 2025
- AstraZeneca PLC Files 6-K Report — 6-K · Dec 1, 2025
- AstraZeneca's Imfinzi Approved for Early Gastric Cancer in US — 6-K · Nov 26, 2025
- AstraZeneca Announces Maryland Manufacturing Investment — 6-K · Nov 24, 2025
- AstraZeneca's Koselugo Approved in US — 6-K · Nov 20, 2025
- Astrazeneca PLC 6-K Filing — 6-K · Nov 17, 2025
- Astrazeneca PLC 6-K Filing — 6-K · Nov 14, 2025
- AstraZeneca PLC Files Director Shareholding Report — 6-K · Nov 10, 2025
- AstraZeneca PLC Files 9M and Q3 2025 Results — 6-K · Nov 6, 2025
- Astrazeneca PLC 6-K Filing — 6-K · Nov 3, 2025
- AstraZeneca PLC Files November 2025 6-K Report — 6-K · Nov 3, 2025
- AstraZeneca's Koselugo Approved in EU for NF1 — 6-K · Oct 28, 2025
- Tezspire Approved in EU for CRSwNP — 6-K · Oct 22, 2025
- AstraZeneca's SAPHNELO gets positive EU opinion — 6-K · Oct 20, 2025
- AstraZeneca Agrees to Lower US Medicine Prices — 6-K · Oct 14, 2025
- AstraZeneca's BAXDROSTAT Trial Meets Primary Endpoint — 6-K · Oct 7, 2025
- AstraZeneca's Dato-DXd Shows Improved Survival in Breast Cancer Trial — 6-K · Oct 6, 2025
- AstraZeneca PLC Files 6-K Report — 6-K · Oct 1, 2025
- AstraZeneca Harmonizes Listing Structure — 6-K · Sep 29, 2025
- AstraZeneca PLC Files 6-K Report — 6-K · Sep 29, 2025
- AstraZeneca PLC Files 6-K Shareholding Report — 6-K · Sep 25, 2025
- AstraZeneca's Tezspire gets EU nod for nasal polyps — 6-K · Sep 22, 2025
- AstraZeneca's RESOLUTE Trial Meets Primary Endpoint — 6-K · Sep 17, 2025
- AstraZeneca Files Routine 6-K Report — 6-K · Sep 2, 2025
- AstraZeneca PLC Files 6-K Report — 6-K · Aug 28, 2025
- AstraZeneca PLC Files Form 6-K — 6-K · Aug 26, 2025
- AstraZeneca PLC Files Form 6-K — 6-K · Aug 21, 2025
- AstraZeneca PLC Files 6-K for Director Shareholding — 6-K · Aug 18, 2025
- AstraZeneca PLC Files Form 6-K — 6-K · Aug 15, 2025
- AstraZeneca PLC Files 6-K Report — 6-K · Aug 12, 2025
- AstraZeneca PLC Files Form 6-K for August 2025 — 6-K · Aug 1, 2025
- AstraZeneca PLC Files 6-K for Q2 2025 — 6-K · Jul 29, 2025
- AstraZeneca's Gefulimab Nanobody Hits Phase III Endpoints — 6-K · Jul 24, 2025
- AstraZeneca to Invest $50 Billion in US — 6-K · Jul 22, 2025
- AstraZeneca Updates on AL Amyloidosis Drug Anselamimab — 6-K · Jul 16, 2025
- AstraZeneca's BAXdrostat Meets Primary Endpoint in Phase III Trial — 6-K · Jul 14, 2025
- AstraZeneca's Imfinzi gets EU approval for Stage III NSCLC — 6-K · Jul 7, 2025
- AstraZeneca PLC Files July 2025 6-K Report — 6-K · Jul 1, 2025
- AstraZeneca's Datroway Approved in US for Lung Cancer — 6-K · Jun 24, 2025
- AstraZeneca Collaborates with CSPC — 6-K · Jun 13, 2025
- AstraZeneca PLC Files 6-K on Director Shareholdings — 6-K · Jun 12, 2025